Sangamo Therapeutics (SGMOQ) Income towards Parent Company (2010 - 2025)

Sangamo Therapeutics' Income towards Parent Company history runs 16 years deep, the most recent figure standing at -$37.4 million for Q4 2025.

• On a quarterly basis, Income towards Parent Company fell 59.94% year-over-year to -$37.4 million in Q4 2025; TTM through Dec 2025 was -$122.9 million, a 25.52% decrease from a year earlier, with the FY2025 full-year figure at -$122.9 million, down 25.52% from the prior year.
• Income towards Parent Company eased to -$37.4 million in Q4 2025 per SGMOQ's latest filing, from -$34.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $21.1 million in Q1 2023 and bottomed at -$114.5 million in Q2 2023.
• The 5-year median for Income towards Parent Company is -$43.6 million (2022), against an average of -$42.5 million.
• Across the five-year window, Income towards Parent Company tumbled 3063.26% in 2021 and surged 148.05% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$37.5 million in 2021, then tumbled by 38.53% to -$51.9 million in 2022, then fell by 16.08% to -$60.3 million in 2023, then soared by 61.2% to -$23.4 million in 2024, then tumbled by 59.94% to -$37.4 million in 2025.
• Per Business Quant, the three latest SGMOQ Income towards Parent Company figures stand at -$37.4 million (Q4 2025), -$34.9 million (Q3 2025), and -$20.0 million (Q2 2025).